Project Grant R21CA300956
Award Date
3/17/25
Completion Date
2/28/27
Dollars Obligated
$279K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98195, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research) provides $645,196 to the University of Washington to conduct research aimed at discovering and characterizing non-coding genetic variations that may contribute to inherited breast and ovarian cancer risk. The key products or services to be delivered under this 5-year award include:
Using long-read sequencing to identify rare non-coding variants in the regulatory regions of known...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), provides $219,491 to Emory University to conduct research on the dynamic regulation of HER2 expression in breast cancer. The research aims to characterize the epigenetic and epigenomic features that drive the rapid and plastic conversion between HER2-positive and HER2-low tumor cell states, in the absence of genetic alterations. By employing cell culture models...
The National Cancer Institute (NCI) awarded a $402,600 Project Grant (CFDA 93.393 - Cancer Cause and Prevention Research) to the Fred Hutchinson Cancer Center in Seattle, Washington. The purpose of this 4-year award, with a period of performance from July 1, 2024 to June 30, 2028, is to understand the extent to which commercially insured cancer patients, particularly the near-poor and those with chronic conditions, are at risk for shortfalls in care and adverse financial outcomes in the...
This federal Project Grant award of $2,136,715.00 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) is funding research to harness DNA methylation in peripheral blood for improved colorectal cancer prevention. The primary awardee, Harvard T.H. Chan School of Public Health, is leading a multi-institutional effort that includes sub-awards to Dana-Farber Cancer Institute and Boston University. The key research activities involve using...
The National Cancer Institute (NCI) awarded a $505,613 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the Fred Hutchinson Cancer Center in Seattle, WA to develop statistical and computational approaches for precision cancer prevention. The key objectives are to:
Create deep learning models that identify tumor subtypes predictive of poor outcomes and integrate individual risk factor data to enhance risk stratification for tailored prevention strategies.
Develop...
The National Cancer Institute (NCI) awarded a 5-year, $456,048 Project Grant (CFDA 93.396 - Cancer Biology Research) to Cold Spring Harbor Laboratory (CSHL) to investigate the central mechanisms underlying disruptions to the circadian rhythm of glucocorticoids (e.g., cortisol) in breast cancer. The goal is to systematically determine where along the hypothalamic-pituitary-adrenal (HPA) axis this dysfunction occurs, identify the driving mechanisms, and develop interventions to restore a robust...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $447,340 to the University of Miami to investigate epigenetic mechanisms that contribute to endocrine-resistant breast cancer. The researchers aim to identify vulnerabilities in the CoREST-SWI/SNF chromatin remodeling axis that can be targeted to enhance survival for patients with metastatic, endocrine-resistant breast cancer. Specifically, the study will examine the role of the...
This $597,119 federal Project Grant award, issued by the National Cancer Institute under CFDA Program 93.396 - Cancer Biology Research, supports research by the Fred Hutchinson Cancer Center in Seattle, WA to investigate the role of the NRF2 transcription factor in regulating the tumor immune microenvironment and disseminated tumor cell outgrowth in breast cancer. The research aims to define the mechanisms by which NRF2 suppresses pro-inflammatory signaling in breast tumors, and to evaluate...
The National Cancer Institute (NCI) awarded a $230,010 Project Grant (CFDA 93.396 - Cancer Biology Research) to the University of Chicago to develop and apply a novel epigenome sequencing platform called Glycosylase-Implemented Epigenome Sequencing (GLIMP-SEQ). The goal is to enable high-sensitivity and high-fidelity profiling of 5-methylcytosine (5mC), a key epigenetic marker, in degraded clinical samples such as formalin-fixed, paraffin-embedded (FFPE) tissues and cell-free DNA (cfDNA).
In...
The National Cancer Institute (NCI) awarded a $455,111 Project Grant under CFDA 93.393 "Cancer Cause and Prevention Research" to the Sloan-Kettering Institute for Cancer Research in New York. The 2-year grant, awarded on September 5, 2023, will support research to "Leverage the Hidden Genome to Recover the Missing Heritability of Cancer." The project aims to 1) estimate additional heritability that can be explained by the "hidden genome" (regions of unknown...